Lupin Bioresearch centre successfully passes USFDA Inspection without observations

14 Mar 2023 , 02:50 AM

Lupin Limited, a leading global pharmaceutical company, reported today that the Bioresearch Centre situated in Pune, India, underwent inspection USFDA. The inspection did not result in any adverse observation. 

Lupin Bioresearch Centre performs various studies such as BA/BE, PK/PD, In-vitro BE, and biosimilar assessments. The inspection concluded without any findings or remarks.

Nilesh Gupta, the Managing Director of Lupin, expressed satisfaction in declaring that the Lupin Bioresearch Centre had passed its seventh consecutive onsite assessment, thereby reiterating Lupin’s dedication to ensuring patient safety and maintaining the highest standards of quality and compliance.

Recently, Lupin also announced that USFDA concluded a pre-approval and GMP inspection at its API manufacturing facility located in Visakhapatnam (Vizag), India with no observations.

At around 2.51 PM, Lupin was trading at Rs656.90, against the previous close of Rs654.30 on NSE. The counter touched an intraday high and low of Rs668.90 and Rs652.20 respectively.

For feedback and suggestions, write to us at [e-mail]